{"title":"利培酮治疗首发精神分裂症疗效的meta分析。","authors":"Hua Yang, Haili Wu","doi":"10.29399/npa.28712","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia.</p><p><strong>Methods: </strong>A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed.</p><p><strong>Results: </strong>A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone.</p><p><strong>Conclusion: </strong>Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"61 4","pages":"351-357"},"PeriodicalIF":1.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638566/pdf/","citationCount":"0","resultStr":"{\"title\":\"Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.\",\"authors\":\"Hua Yang, Haili Wu\",\"doi\":\"10.29399/npa.28712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia.</p><p><strong>Methods: </strong>A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed.</p><p><strong>Results: </strong>A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone.</p><p><strong>Conclusion: </strong>Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.</p>\",\"PeriodicalId\":51142,\"journal\":{\"name\":\"Noropsikiyatri Arsivi-Archives of Neuropsychiatry\",\"volume\":\"61 4\",\"pages\":\"351-357\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638566/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Noropsikiyatri Arsivi-Archives of Neuropsychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.29399/npa.28712\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.29399/npa.28712","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.
Introduction: First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia.
Methods: A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed.
Results: A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone.
Conclusion: Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.
期刊介绍：
Archives of Neuropsychiatry (Arch Neuropsychiatry) is the official journal of the Turkish Neuropsychiatric Society. It is published quarterly, and four editions annually constitute a volume.
Archives of Neuropsychiatry is a peer reviewed scientific journal that publishes articles on psychiatry, neurology, and behavioural sciences. Both clinical and basic science contributions are welcomed. Submissions that address topics in the interface of neurology and psychiatry are encouraged. The content covers original research articles, reviews, letters to the editor, and case reports.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
